What Drugs Should You Not Take With Bupropion? A Complete Interaction Guide

Bupropion is contraindicated with monoamine oxidase inhibitors (MAOIs) and should never be combined with methylene blue due to serotonin syndrome risk. Additionally, bupropion's potent inhibition of the CYP2D6 enzyme creates major interactions with tramadol, codeine, metoclopramide, and other drugs metabolized by this pathway, requiring careful dosing adjustments or avoidance. Understanding these interactions is critical because bupropion is one of the most widely prescribed antidepressants in the United States, affecting millions of patients who may also need pain relief, nausea management, or other common medications.

What Is Bupropion and How Does It Work?

Bupropion is an atypical antidepressant belonging to the aminoketone class. Unlike selective serotonin reuptake inhibitors (SSRIs) that boost serotonin, bupropion works primarily by blocking the reuptake of dopamine and norepinephrine in the brain. This mechanism makes it useful for depression, seasonal affective disorder, and smoking cessation (sold under the brand name Zyban).

The drug is metabolized extensively by the liver through the cytochrome P450 enzyme system, particularly CYP2D6, CYP3A4, and CYP2C19 pathways. This hepatic metabolism is where most of bupropion's clinically significant interactions originate. Because bupropion is a strong inhibitor of CYP2D6—one of the body's most important drug-metabolizing enzymes—it can dramatically increase blood concentrations of other medications that depend on this enzyme for breakdown.

Bupropion also has a unique property: it lowers the seizure threshold. This means it makes seizures more likely to occur, especially at higher doses or in patients with predisposing factors. When bupropion is combined with other seizure-lowering drugs, this risk multiplies significantly.

FDA-Identified Contraindications: Drugs Never to Take With Bupropion

The FDA has identified one absolute contraindication and several major interactions that warrant extreme caution or avoidance:

Monoamine Oxidase Inhibitors (MAOIs)

This is the only true contraindication listed in bupropion labeling. MAOIs (phenelzine, tranylcypromine, isocarboxazid, and others) must never be taken with bupropion due to the risk of severe hypertensive reactions and potential serotonin syndrome. The mechanism is straightforward: both drug classes increase monoamine concentrations in the synapse, and when combined, norepinephrine can accumulate to dangerously high levels, causing a hypertensive crisis. Blood pressure can spike to life-threatening levels within minutes of the interaction. Patients must wait at least 14 days after stopping an MAOI before starting bupropion, and vice versa.

Methylene Blue

Methylene blue is a potent reversible inhibitor of monoamine oxidase that is occasionally used as a treatment for methemoglobinemia or, in rare psychiatric settings, for treatment-resistant depression. When combined with bupropion, methylene blue can precipitate serotonin syndrome—a potentially fatal medical emergency characterized by muscle rigidity, hyperthermia, altered mental status, and cardiovascular instability. The FDA specifically warns against this combination in bupropion labeling.

Major Interactions: CYP2D6-Mediated Drug Accumulation

Bupropion's most significant mechanism of harm is its potent inhibition of the CYP2D6 enzyme. Approximately 7-10% of the population are slow metabolizers of CYP2D6 substrates due to genetic variation, and these individuals are at especially high risk for accumulation when taking bupropion with CYP2D6-dependent drugs. However, even normal metabolizers can experience clinically significant elevation in drug concentrations.

Tramadol and Tramadol/Acetaminophen Combinations

The FDA has issued multiple warnings about combining bupropion with tramadol. This interaction is particularly dangerous because tramadol itself has seizure-lowering properties and can cause serotonin syndrome. When bupropion inhibits CYP2D6, it prevents the conversion of tramadol to its active metabolite M1, which is responsible for much of tramadol's analgesic effect. However, unchanged tramadol accumulates in the bloodstream, and both the parent drug and the serotonergic effects of tramadol are enhanced. The result can be:

• Increased seizure risk (both drugs lower seizure threshold)
• Serotonin syndrome (tremor, agitation, hyperthermia, rigidity)
• Paradoxically, reduced pain relief (due to decreased M1 formation)
• Opioid withdrawal-like symptoms or toxicity

The FDA recommends avoiding this combination entirely, or if unavoidable, using the lowest possible dose of tramadol with close clinical monitoring.

Codeine and Codeine/Acetaminophen Combinations

Codeine is a prodrug that requires conversion to morphine (via CYP2D6) to produce most of its analgesic effect. When bupropion inhibits CYP2D6, codeine cannot be efficiently converted to morphine, meaning the pain relief is reduced while codeine itself accumulates. Additionally, when the patient stops taking bupropion, the sudden improvement in CYP2D6 function can cause a rapid surge in morphine formation, leading to opioid overdose and potentially fatal respiratory depression. Dosing adjustments may be necessary, and careful monitoring is essential if this combination cannot be avoided.

Metoclopramide (Reglan)

Metoclopramide is a dopamine antagonist used for nausea and gastroesophageal reflux. Bupropion inhibition of CYP2D6 significantly increases metoclopramide concentrations, raising the risk of extrapyramidal side effects—involuntary muscle movements that can be permanent (tardive dyskinesia). The FDA labeling recommends reducing the metoclopramide dose when used with bupropion. For patients on both drugs, watch for tremor, muscle stiffness, abnormal eye movements, or jaw clenching.

Cyclobenzaprine (Flexeril)

This muscle relaxant has documented postmarketing cases of serotonin syndrome when combined with bupropion. Although cyclobenzaprine's mechanism is not fully understood in this context, the risk is significant enough that close monitoring or avoidance is recommended. Symptoms to watch for include muscle rigidity, altered mental status, and fever.

Major Interactions: Seizure Threshold Lowering

Corticosteroids (Prednisone and Others)

Both bupropion and systemic corticosteroids independently lower the seizure threshold. When used together, the risk becomes additive and potentially severe. This interaction is particularly common in real-world practice because bupropion is used for depression in patients with autoimmune conditions, inflammatory bowel disease, and other disorders treated with prednisone. If this combination is necessary, start with low doses of both drugs and titrate slowly while monitoring closely for seizure warning signs (aura, muscle twitching, brief loss of consciousness).

Clinical Scenarios: Real-World Examples

Scenario 1: The Chronic Pain Patient with Depression

A 52-year-old woman has been stable on bupropion 300 mg daily for depression for two years. She injures her knee and her orthopedic surgeon prescribes tramadol/acetaminophen 50/325 mg twice daily for pain control. Without checking the interaction, the patient begins taking both medications. Within three days, she experiences tremors, jaw clenching, and significant anxiety. On day five, she has a brief seizure while at work. Her emergency room evaluation reveals elevated tramadol concentrations due to CYP2D6 inhibition by bupropion. The interaction was entirely preventable: her primary care doctor or pharmacist should have recommended ibuprofen or a non-opioid alternative, or if opioid analgesia was truly necessary, a drug not metabolized by CYP2D6 (such as morphine or fentanyl) would have been safer. The lesson: bupropion patients with acute pain require proactive, careful medication selection.

Scenario 2: The MAOI Transition

A 67-year-old man with treatment-resistant depression has been on the MAOI phenelzine 60 mg daily for three years with good response. His psychiatrist decides to switch to bupropion because of dietary restrictions associated with the MAOI. The psychiatrist correctly instructs the patient to stop phenelzine and wait 14 days before starting bupropion. However, the patient's primary care doctor, unaware of the transition, continues to prescribe fluoxetine (an SSRI) the patient had been taking on the side. When the patient starts bupropion on day 15, he suddenly develops severe headache, palpitations, and a blood pressure of 180/110 mmHg. The emergency room physician recognizes this as a hypertensive crisis from the MAOI-like properties of the combination. This scenario underscores the critical importance of clear communication during medication transitions. The patient should have had a washout period from all serotonergic drugs, not just the MAOI.

Moderate Interactions to Monitor

Beyond the major interactions listed above, bupropion can interact with other CYP2D6 substrates at a moderate severity level. These include:

• Antiarrhythmics (flecainide, propafenone) – increased risk of cardiac arrhythmias
• Antipsychotics (haloperidol, risperidone) – increased risk of extrapyramidal symptoms
• Beta-blockers (metoprolol, carvedilol) – increased risk of bradycardia and hypotension
• Selective serotonin reuptake inhibitors (SSRIs like paroxetine, fluoxetine) – increased serotonin syndrome risk, though not as severe as with MAOIs

These interactions typically require dose adjustments or close monitoring rather than absolute avoidance. Your prescribing doctor or pharmacist should be aware of all medications before adding bupropion to a regimen.

Top Bupropion Interactions at a Glance

• MAOIs (phenelzine, tranylcypromine): Severity – Contraindicated. Risk – Hypertensive crisis, serotonin syndrome. Action – Absolute avoidance; 14-day washout required between drugs.
• Methylene blue: Severity – Major. Risk – Serotonin syndrome (potentially fatal). Action – Avoid concomitant use.
• Tramadol and tramadol/acetaminophen: Severity – Major. Risk – Seizures, serotonin syndrome, reduced analgesia. Action – Avoid if possible; if necessary, use lowest dose with monitoring.
• Codeine and codeine/acetaminophen: Severity – Major. Risk – Reduced analgesia; risk of morphine overdose upon discontinuation. Action – Dosage reduction needed; close monitoring required.
• Metoclopramide: Severity – Major. Risk – Extrapyramidal symptoms, tardive dyskinesia. Action – Reduce metoclopramide dose; monitor for involuntary movements.
• Cyclobenzaprine: Severity – Major. Risk – Serotonin syndrome. Action – Avoid or monitor closely.
• Prednisone and other corticosteroids: Severity – Major. Risk – Additive seizure threshold lowering. Action – Use lowest doses; slow titration; seizure monitoring.
• Tricyclic antidepressants (amitriptyline, nortriptyline): Severity – Moderate to Major. Risk – Increased TCA levels, cardiac arrhythmias. Action – Dosage adjustment; ECG monitoring may be needed.
• SSRIs (paroxetine, fluoxetine): Severity – Moderate. Risk – Serotonin syndrome. Action – Monitor closely; consider alternative antidepressants.
• Antiarrhythmics (flecainide, propafenone): Severity – Moderate. Risk – Arrhythmias. Action – Dosage reduction; cardiac monitoring.

What Patients Should Tell Their Doctor or Pharmacist

Before starting bupropion or when bupropion is being considered, inform your healthcare provider about:

• All current medications, including over-the-counter drugs, supplements, and herbal products
• Any history of seizures or conditions that lower seizure threshold (head injury, eating disorders, abrupt alcohol withdrawal)
• Recent use of MAOIs (you must have a 14-day washout period)
• Chronic pain conditions that might require tramadol, codeine, or other opioids
• History of nausea or reflux that might require metoclopramide
• Kidney or liver disease, which can affect drug metabolism
• Bipolar disorder (bupropion can trigger manic episodes)

Similarly, when your doctor prescribes a new medication while you are on bupropion, explicitly state that you are taking bupropion and ask whether the new drug has any documented interactions. Your pharmacist is your second line of defense; pharmacy computer systems flag major interactions, but human review is still essential because some important interactions may not be captured in automatic systems.

What Should You Do If You Are on Bupropion and Need a Medication on the Interaction List?

For Tramadol or Codeine Pain Relief

First-line alternatives include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs like ibuprofen or naproxen), or topical pain medications. If opioid therapy is truly necessary, consider opioids not significantly metabolized by CYP2D6, such as morphine, oxymorphone, or fentanyl patches. If the CYP2D6-dependent opioid cannot be avoided, reduce the starting dose significantly and monitor closely for side effects or signs of overdose.

For Nausea (Metoclopramide Needed)

Consider alternatives like ondansetron (Zofran), a 5-HT3 antagonist not significantly metabolized by CYP2D6, or domperidone (available outside the US). If metoclopramide is necessary, reduce the dose and monitor for involuntary movements.

For Muscle Spasms (Cyclobenzaprine)

Physical therapy, heat/ice, and non-pharmacological approaches are preferred. If medication is needed, tizanidine or baclofen may have fewer interactions with bupropion, though consultation with your doctor is essential.

For Depression Augmentation or Switching Antidepressants

If bupropion is not providing adequate relief and your doctor considers adding another antidepressant, be aware that SSRIs and tricyclic antidepressants can interact with bupropion through both CYP2D6 inhibition and serotonergic mechanisms. Your psychiatrist may choose to augment with a drug that works through a different mechanism (such as mirtazapine, which affects histamine and norepinephrine) rather than adding a serotonergic agent.

Genetic Testing and CYP2D6 Metabolism

If you are starting bupropion or taking a CYP2D6-dependent medication like tramadol, you might ask your doctor about pharmacogenetic testing to determine your CYP2D6 metabolizer status. Genetic testing is available and can identify whether you are a poor, intermediate, extensive, or ultra-rapid metabolizer. Poor and intermediate metabolizers are at particularly high risk for drug accumulation when bupropion is added. While not routinely ordered, this testing can be valuable for patients on multiple CYP2D6 substrates or those who have had adverse effects from medications.

Key Takeaways

• Never combine bupropion with MAOIs or methylene blue. These are absolute contraindications carrying risk of life-threatening hypertensive crisis or serotonin syndrome. A 14-day washout period is required between bupropion and MAOIs.
• Bupropion strongly inhibits CYP2D6, causing dangerous accumulation of tramadol, codeine, metoclopramide, and other drugs. If these medications are necessary, doses must be reduced and clinical monitoring is essential. For tramadol and codeine, non-CYP2D6-dependent alternatives are strongly preferred.
• Both bupropion and certain medications (corticosteroids, tramadol) lower seizure threshold. Combining these requires careful dose titration, slow increases, and close seizure monitoring, especially in at-risk populations.
• Inform your doctor and pharmacist of all medications before starting bupropion or adding any new drug to a bupropion regimen. Many interactions can be prevented or managed with proper planning and dose adjustments.
• Watch for warning signs of serious interactions: muscle rigidity or involuntary movements (serotonin syndrome, extrapyramidal effects), severe headache or elevated blood pressure (MAOI interaction), brief loss of consciousness (seizures), or persistent jaw clenching and tremor. Seek immediate medical attention if these occur.

Sources

• FDA Drug Labeling via OpenFDA: open.fda.gov – Bupropion HCl labeling, including boxed warnings and contraindications
• FDA Drug Labeling via OpenFDA: Tramadol labeling – CYP2D6 interaction and serotonin syndrome warnings
• FDA Drug Labeling via OpenFDA: Metoclopramide labeling – Extrapyramidal symptom risk with CYP2D6 inhibitors
• FDA Drug Labeling via OpenFDA: Codeine/Acetaminophen labeling – CYP2D6 interaction and morphine overdose risk
• National Institutes of Health (NIH) National Library of Medicine – CYP2D6 substrate database: pubchem.ncbi.nlm.nih.gov
• UpToDate: Bupropion – drug interactions and adverse effects (clinically reviewed resource)
• FDA Safety Alert (2017): Tramadol and risk of seizures with CYP2D6 inhibitors – fda.gov

Check Your Complete Medication List for Interactions

Bupropion is a powerful and beneficial medication for millions of patients managing depression and other conditions. However, its significant drug interactions demand careful attention. The interactions covered in this guide represent the most severe and well-documented risks, but they are not exhaustive. Every medication you take—including over-the-counter pain relievers, cold medicines, supplements, and herbal products—can potentially interact with bupropion. Rather than relying on memory or spot-checking individual combinations, use a comprehensive drug interaction checker to evaluate your entire medication regimen. Visit checkdruginteractions.com to enter all your current medications and receive a complete, FDA-informed interaction report. This takes just a few minutes and can prevent serious adverse events. When in doubt, ask your pharmacist or doctor before starting any new medication while on bupropion.